

CONSOLIDATED RESULTS		Particulars	STANDALONE			
Quarter Ended on 31st March 2009	Year ended on 31st March 2009		Quarter Ended on 31st March 2009	Quarter Ended on 31st March 2008	Year ended on 31st March 2009	Previous Year ended on 31st March, 2008
		1 (a) Net Sales / Income from Operations				
14218	67831	Domestic	14218	16476	67831	71076
11688	45536	Exports	10278	10333	44126	31585
25906	113367	Total	24496	26809	111957	102661
312	1761	Less : Excise Duty	312	529	1761	2336
25594	111606	Net Sales / Income from Operations	24184	26280	110196	100325
116	410	(b) Other Operating Income	116	139	410	518
25710	112016	Total Income	24300	26419	110606	100843
		2 Expenditure				
(710)	(3073)	(a) Decrease/(increase) in stock in trade and work in progress	(710)	716	(3073)	(1892)
9390	43313	(b) Consumption of Raw Materials & Packing Materials	9390	9758	43313	33012
3878	14876	(c) Purchase of traded goods	2863	2900	13861	17228
3474	13169	(d) Employees' Cost	3474	2597	13169	9762
1518	4030	(e) Research and Development Expense	1518	972	4030	4339
24	788	(f) Excise Duty	24	34	788	881
6608	25979	(g) Other Expenditure	6608	5983	25966	22484
24182	99082	Total	23167	22960	98054	85814
1528	12934	3 Profit from Operations before Other Income, Interest, Depreciation Foreign Exchange gain / (loss) & Exceptional Items	1133	3459	12552	15029
19	104	4 Other Income	19	66	104	577
1547	13038	5 Profit/(Loss) before Interest, Depreciation, Foreign Exchange gain / (loss) & Exceptional Items	1152	3525	12656	15606
982	3831	6 Depreciation	982	875	3831	3277
714	4006	7 Interest (Net)	714	922	4006	3305
(149)	5201	8 Profit/(Loss) after Interest but before Foreign Exchange gain / (loss) & Exceptional Items	(544)	1728	4819	9024
(71)	(3536)	9 Foreign Exchange gain / (loss) (Net)	(42)	(176)	(3507)	81
(220)	1665	10 Profit / (Loss) before Exceptional Items	(586)	1552	1312	9105
-	-	11 Exceptional Items				
-	-	Add : Profit on sale of Land	-	-	-	2255
-	752	Less : Provision for Diminution in Investment	-	-	752	-
-	-	Intangible Asset Written off	-	17682	-	17682
-	-	Less : Transfer from General Reserve	-	10258	-	10258
-	-	Less : Transfer from Share Premium Account	-	2917	-	2917
-	-	Less : Deferred Tax Asset	-	4507	-	4507
(220)	913	12 Net Profit / (Loss) from Ordinary Activities before Tax	(586)	1552	560	11360
70	220	13 Tax Expense	70	45	220	148
(78)	50	Less : Provision for Fringe Benefit Tax & Wealth Tax	(78)	0	50	-
(28)	(3)	Less : Provision for Current Tax	(28)	27	(3)	47
37	436	Less/(Add) : Provision for Deferred Tax Liability/(Assets)	37	54	436	54
		Add : Provision of Income Tax of earlier years written back (Net)				
(147)	1082	14 Net Profit / (Loss) from Ordinary Activities after Tax	(513)	1534	729	11219
2744	2744	15 Paid up Equity Share Capital (Face value of share Rs 2/-)	2744	2769	2744	2769
	30309	16 Reserves excluding Revaluation Reserve			29955	31367
(0.11)	0.78	17 Earnings Per Share (EPS) Basic & Diluted EPS after Extraordinary items	(0.37)	1.10	0.53	8.10
52439181	52439181	18 Public Shareholding	52439181	53701900	52439181	53701900
38.22	38.22	- Number of Shares	38.22	38.79	38.22	38.79
		- Percentage of Shareholding				
		19 Promoters and Promoter Group Shareholding				
		(a) Pledged / Encumbered				
22250000	22250000	Number of Shares	22250000		22250000	
26.25	26.25	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	26.25		26.25	
16.22	16.22	Percentage of Shares (as a % of the total share capital of the Company)	16.22		16.22	
		(b) Non - Encumbered				
62503005	62503005	Number of Shares	62503005		62503005	
73.75	73.75	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	73.75		73.75	
45.56	45.56	Percentage of Shares (as a % of the total share capital of the Company)	45.56		45.56	

Notes :

- 1 The Board has recommended dividend on Equity Shares at Rs.0.40 per share i.e.20% for the year ended on 31.03.2009
- 2 The Company is engaged in Pharmaceutical business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS - 17)
- 3 Foreign Exchange gain / (loss) - (Net) includes realized and unrealized exchange gain/ (loss) on restatement of foreign currency borrowing and forward sale of US dollars.
- 4 In terms of decision of the Board of Directors dated November 14, 2008 the Company offered to buy back its equity shares of face value of Rs.2/- each, upto a maximum amount of Rs.3300 lakhs at a maximum price of Rs.55/- per share through the methodology of "Open market purchases through stock exchanges" using the electronic trading facilities of the Bombay Stock Exchange Limited (BSE) and the National Stock Exchange of India Limited (NSE). After completion of regulatory formalities, the Company commenced the buy back on December 8, 2008.

As on March 31, 2009 the Company has bought back 12,62,844 equity shares at an average price of Rs. 31.46 for a total consideration of Rs. 396.76 lacs which is about 12.02% of the total buy – back size of Rs. 3300 lacs. The Company has extinguished 12,62,719 shares on or before 31st March, 2009. The rest 125 shares were extinguished 15th April, 2009.

- 5 The un-audited result of the Subsidiary Company - Alembic Global Holding SA of Alembic Limited for the quarter and year ended on 31st March, 2009 are included above. There were no operations in Subsidiary Company till 31st March 2008 hence corresponding previous year's figure are not applicable for consolidated results.
- 6 Details of Investors' Complaints for the quarter ended on 31st March, 2009 : Unresolved at the beginning of the quarter-NIL Received during the quarter-8, Disposed off during the quarter-8 , Unresolved at the end of the quarter - NIL.
- 7 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited

Place : Vadodara
Date : 8th May, 2009

Chirayu Amin

Visit us at www.alembic-india.com